Pioneering the development of novel

immuno-oncology and immune therapies

Our Team

The HaemaLogiX team is researching immune-based treatments that target unique antigens on malignant cells to improve the quality of life of patients suffering from blood cancers.

Our Pipeline

Our research platform involves multiple approaches in treating Multiple Myeloma – a blood cancer, and AL Amyloidosis – a life-threatening abnormal protein build-up in tissues and organs.

Our Innovation

Following the discovery of two unique antigens on malignant Bone Marrow Cells, we are developing Monoclonal Antibodies, CAR T cell Therapies and Bispecific Antibodies that specifically target those malignant cells.

News & Events

HaemaLogiX announces issuance of Australian patent for KMA.CAR

HaemaLogiX initiates collaboration with Universidad de Navarra

Prof Andrew Spencer presents KappaMab Phase 2b interim analysis results at ASH 2019

redTextLogo